Certain anti-obesity and diabetes drugs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors, have proven effective in managing diabetes in liver transplant recipients. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.